BARCELONA, SPAIN and CAMBRIDGE, MA--(Marketwired - January 30, 2017) - Oryzon Genomics (MAD: ORY) (ISIN Code: ES0167733015), a public clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical need, announced today that it will present an overview of its 2 clinical stage compounds ("ORY-1001"and "ORY-2001") at the Keystone Symposia on Epigenetics and Human Disease being held January 29th- February 2nd, 2017 at the Sheraton Seattle Hotel in Seattle, Washington, USA.
Dr. Tamara Maes, Oryzon's Chief Scientific Officer, is scheduled to present on Thursday, February 2nd, 2017 at 5pm PST in the Grand Ballroom CD. In the presentation entitled "Development of Lysine Specific Demethylase Inhibitors for Oncological and Neurodegenerative Disease," she will discuss the role of LSD1 in oncology and CNS. Dr. Maes will also summarize encouraging top line results from a Phase I-IIA clinical trial in Acute Leukemia of ORY-1001 as well as the most recent progress with ORY-2001, in development for the treatment of neurodegenerative disorders and which is currently finalizing a Phase I trial in healthy volunteers.
This conference is aimed at interrogating the most current knowledge surrounding the epigenetic events while relating this to developmental and disease models. In addition, this conference will highlight the impact that preclinical and clinical epigenetic therapeutics have on a panel of diseases including cancer and neurological disorders. By presenting these various aspects associated with epigenetics and diverse diseases, this unique forum hopes to promote dynamic discussions, interactions and collaborations that will impact the understanding of these diseases and potential treatment strategies.
About Oryzon
Founded in 2000 in Barcelona, Spain, Oryzon (ISIN Code: ES0167733015) is a clinical stage biopharmaceutical company considered as the European champion in Epigenetics. The company has one of the strongest portfolios in the field and a clinical asset already partnered with Roche. Oryzon's LSD1 program is currently covered by + 20 patent families and has rendered two compounds in clinical trials. In addition, Oryzon has ongoing programs for developing inhibitors against other epigenetic targets. The company has a strong technological platform for biomarker identification and performs biomarker and target validation for a variety of malignant and neurodegenerative diseases. Oryzon's strategy is to develop first in class compounds against novel epigenetic targets through Phase II clinical trials, at which point it is decided on a case-by-case basis to either keep the development in-house or to partner or outlicense the compound for late stage development and commercialization. The company has offices in Barcelona and Cambridge, Massachusetts. For more information, visit www.oryzon.com.